Clinical Trial Update: Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial combining pyrotinib with subcutaneous trastuzumab and capecitabine for HER2-positive breast cancer is listed as not yet recruiting, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Herceptin SC (trastuzumab)
• Tyvyt (Sintilimab)
• Xeloda (capecitabine)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING